Pfizer remains our top drug stock

We now see several promising opportunities emerging in the pharmaceutical drug industry, and we will probably recommend more drug stocks in the next few years. For now, we feel Pfizer offers our readers the best combination of growth and income in a pharma stock. Since… Read More

A great choice for COVID-19 gains

PFIZER INC. $37 is a buy. The company (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares outstanding: 5.6 billion; Market cap: $207.2 billion; Price-to-sales ratio: 4.1; Dividend yield: 4.1%; TSINetwork Rating: Above Average; www.pfizer.com) saw its revenue in the first quarter of 2020 fall 8.3%,… Read More

You’ll profit from Pfizer’s new focus

Under a new long-term strategy, Pfizer is concentrating on what it does best: developing new patented drugs that generate strong returns for its shareholders.
As part of that plan, the company is merging its over-the-counter and generic drugs businesses with those of other pharmaceutical firms to… Read More